Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood‐based RAS mutation testing is a viable alternative to standard‐of‐care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAM ing (beads, emulsions, amplification, and magnetics), and compared with DNA sequencing data of respective FFPE (formalin‐fixed paraffin‐embedded) tumor samples. Discordant tissue RAS results were re‐examined by BEAM ing, if possible. The prevalence of RAS mutations detected in plasma (51%) vs. tumor (53%) was similar, in accord with the known prevalence of RAS mutations observed in mCRC patient populations. The positive agreement between plasma and tumor RAS results was 90.4% (47/52), the negative agreement was 93.5% (43/46), and the overall agreement (concordance) was 91.8% (90/98). The high concordance of plasma and tissue results demonstrates that blood‐based RAS mutation testing is a viable alternative to tissue‐based RAS testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Studies evaluating the genomic profiles of primary tumors and metastases have shown discordant results, attributed largely to molecular inter- and intratumor/ metastasis heterogeneity (De Mattos-Arruda et al., 2014; Gerlinger et al., 2012; Mao et al., 2015).”
BackgroundDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“The identification of patients wild-type (WT) for KRAS codons 12 and 13 mutations increased response rates to anti-EGFR therapy by as much as 60% (Douillard et al., 2010; Van Cutsem et al., 2009a) and reinforced the approach of incorporating molecular diagnostics into clinical practice.”
BackgroundMethodK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 2×
“Retrospective analyses of data from randomized controlled clinical trials consistently demonstrate that KRAS exon 2 mutation is a contraindication for the administration of anti-EGFR therapy, regardless of the chemotherapy backbone (Amado et al., 2008; Bokemeyer et al., 2011; Douillard et al., 2010; Karapetis et al.,…”
BackgroundPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“…of RAS, so-called expanded RAS, to include KRAS and NRAS codons 12, 13, 59, 61, 117, 146 can more precisely identify patients with mCRC for anti-EGFR therapy than KRAS codons 12 and 13 testing alone (Bokemeyer et al., 2014; Douillard et al., 2013; Heinemann et al., 2014; Peeters et al., 2014).”
BackgroundLiquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 11×
“Blood-based detection of RAS mutations to guide antiEGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing Wolff Schmiegel1,*, Rodney J. Scott2,3,4,*, Susan Dooley2, Wendy Lewis2, Cliff J. Meldrum2, Peter Pockney4,5, Brian Draganic4,5, Steve Smith4,5,…”
BackgroundInfluentialCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 11×
“Blood-based detection of RAS mutations to guide antiEGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing Wolff Schmiegel1,*, Rodney J. Scott2,3,4,*, Susan Dooley2, Wendy Lewis2, Cliff J. Meldrum2, Peter Pockney4,5, Brian Draganic4,5, Steve Smith4,5,…”
BackgroundInfluentialHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 2×
“This approach has been shown to provide a more precise gauging of the efficacy/failure of anti-EGFR therapy (Diaz et al., 2012; Morelli et al., 2015).”
BackgroundSaltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · cited 2×
“…randomized controlled trials have demonstrated the benefit of treating mCRC patients with monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab (Jonker et al., 2007; Saltz et al., 2004; Tabernero et al., 2007; Van Cutsem et al., 2007).”
BackgroundVan Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156 · cited 2×
“Operationally, an optimal RAS testing procedure for biopsy and surgical resection specimens has yet to be uniformly established (Allegra et al., 2009; van Krieken et al., 2008; Tack et al., 2015).”
BackgroundMethodPeeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005 · cited 1×
“…consistently demonstrate that KRAS exon 2 mutation is a contraindication for the administration of anti-EGFR therapy, regardless of the chemotherapy backbone (Amado et al., 2008; Bokemeyer et al., 2011; Douillard et al., 2010; Karapetis et al., 2008; Peeters et al., 2010; Van Cutsem et al., 2011).”
BackgroundVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Isolation and characterization of DNA from the plasma of cancer patients
Stroun, M., Anker, P., Lyautey, J., Lederrey, C., & Maurice, P. A. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90266-5 · Cited by 373 · cited 1×
“Blood-based tumor genotyping derives from observations that patients with cancer have markedly higher concentrations of circulating cell-free DNA (cfDNA) than healthy individuals (Stroun et al., 1987).”
BackgroundTabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337 · cited 1×
“…randomized controlled trials have demonstrated the benefit of treating mCRC patients with monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab (Jonker et al., 2007; Saltz et al., 2004; Tabernero et al., 2007; Van Cutsem et al., 2007).”
BackgroundKnijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · cited 2×
“Further refinement in biomarker testing was pursued to improve patient outcomes and avoid unnecessary treatment-related side effects and costs, with a focus on KRAS exon 3 and 4 mutations—shown to confer resistance to EGFR antibodies similar to KRAS exon 2 mutations (Janakiraman et al., 2010; Smith et al., 2010).”
BackgroundBEAMing up for detection and quantification of rare sequence variants
Li, M., Diehl, F., Dressman, D., Vogelstein, B., & Kinzler, K. W. (2006) · Nature Methods · doi:10.1038/nmeth850 · Cited by 261
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217 · cited 1×
“Indeed, several studies evaluating intertumor molecular heterogeneity between primary tumors and metastases in the same patient have shown mutational discordance in 3.6–32.4% of cases (Artale et al., 2008; Italiano et al., 2010; Kim et al., 2012; Knijn et al., 2011; Tie et al., 2011).”
BackgroundInfluentialItaliano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114 · cited 1×
“Indeed, several studies evaluating intertumor molecular heterogeneity between primary tumors and metastases in the same patient have shown mutational discordance in 3.6–32.4% of cases (Artale et al., 2008; Italiano et al., 2010; Kim et al., 2012; Knijn et al., 2011; Tie et al., 2011).”
BackgroundInfluential
Cited by
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
The emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
Ahn, J. C., Teng, P., Chen, P., Posadas, E., Tseng, H., Lu, S. C., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.31165 · Cited by 338
Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262
“[102] 98 Beaming RAS 51%/53% 90%/94% 91.”
Metadata
- Authors
- Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., Lucas, A., Shi, E., Namdarian, K., Chan, T., Acosta, D., Ping‐Chang, S., Tannapfel, A., Reinacher‐Schick, A., Uhl, W., Teschendorf, C., Wolters, H., Stern, J., Viebahn, R., Friess, H., Janssen, K., Nitsche, U., Slotta‐Huspenina, J., Pohl, M., Vangala, D., Baraniskin, A., Dockhorn‐Dworniczak, B., Hegewisch‐Becker, S., Ronga, P., Edelstein, D. L., Jones, F. S., Hahn, S., & Fox, S. B.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2017-01-20
- Volume
- 11
- Issue
- 2
- Pages
- 208-219
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2574977410
- Cited by
- 152
- References
- 25
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.